Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross

Acurx Pharmaceuticals, Inc.

2022-Q2 EPS reported -$0.79

Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.
Cash balance $17.1M as of June 30, 2021, following June IPO gross proceeds of $17.25M including overallotment.
Health Holland awarded ~$500K grant to Leiden University to study DNA pol IIIC inhibitors in collaboration with Acurx.
Filed provisional patent for ibezapolstat to treat C. difficile infection with reduced recurrence and improved microbiome health.
SG&A expenses rose to $3.9M in Q2 2021 from $0.5M in Q2 2020, driven by stock-based compensation and professional fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.